Natco Pharma Ltd Share Price
As on 08 July 2025 at 00:48 IST
Natco Pharma Ltd Q4 and Full-Year FY25 Results:
Net profit rose 5% to ₹407 crores, compared to ₹386 crores in Q4 FY24. Total income in Q4 FY25 increased 16% to ₹1,287 crores from ₹1,110 crores in the same period last year. For the financial year 2025, the company reported a net profit of ₹1,885 crores and a total income of ₹4,784 crores, compared with ₹1,388 crores and ₹4,127 crores recorded last year, respectively.
About Natco Pharma Ltd
Natco Pharma Ltd, founded in the year 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets. Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. It is not the top stock in the pharmaceutical sector. However, Natco Pharma maintains a robust market position. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
16.26%
Over 6 Months
-23.70%
Over 1 Year
-17.87%
Over 3 Years
54.18%
Natco Pharma Ltd Summary
Close ₹973.60
Open ₹1,002
High ₹1,006
Low ₹970.30
Volume 15,19,115
Net Turnover (in Cr) ₹149.39
52Wk High ₹1,639
52Wk Low ₹726.80
52Wk High / Low
726.80
1,639
Natco Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹17,438.14
EPS (TTM) 103.31
Book Value (BV) 409.46
Div. Yield 0.62 %
P/E (TTM) 9.42
Price/Book Value 2.38
Delivery % 30.37 %
Face Value 2
Key Ratios
PE Ratio 13.04
PB Ratio 3.05
EV to Sales 4.64
PEG Ratio 0.12
ROA 21.66
ROE 25.38
Debt-Equity 0.05
Net Profit Margin 36.61
Operating Profit Margin 48.80
Natco Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 4,126.90 | 2,811.70 | 2,043.80 | 2,155.70 | 2,022.40 |
| Total Expenses | 2,453.40 | 1,949.80 | 1,841.60 | 1,576.10 | 1,453.70 |
| Profit Before Tax | 1,673.50 | 861.90 | 202.20 | 579.60 | 568.70 |
| Profit After Tax | 1,388.30 | 715.30 | 170 | 442.40 | 458.10 |
| Operating Profit After Depreciation | 1,692.70 | 876.40 | 219.90 | 592.90 | 590.20 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 2,490.80 | 2,426.90 | 2,311.80 | 2,023.20 | 1,584.40 |
| Total Non Current Assets | 2,882.80 | 2,657.10 | 2,611.90 | 2,447.10 | 2,262.20 |
| Total Current Assets | 4,023.50 | 3,000.30 | 2,497.20 | 2,344.80 | 2,325.60 |
| Total Assets | 6,906.30 | 5,657.40 | 5,109.10 | 4,791.90 | 4,587.80 |
| Total Shareholder's Fund | 5,853.10 | 4,873.80 | 4,263.60 | 4,121.60 | 3,773.50 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,211.60 | 849.10 | 46.50 | 298.80 | 417.30 |
| Net Cash Used In Investing Activities | -1,026.20 | -465.30 | 4 | -107.10 | -175 |
| Net Cash Used In Financing Activities | -246.90 | -363 | 34.80 | -185.70 | -250.80 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 3,673.60 | 2,436.50 | 1,862.40 | 1,754.60 | 1,914 |
| Total Expenses | 2,118.30 | 1,665.80 | 1,706.50 | 1,362.40 | 1,330.90 |
| Profit Before Tax | 1,555.30 | 770.70 | 155.90 | 392.20 | 583.10 |
| Profit After Tax | 1,306.60 | 637.10 | 139.10 | 309.50 | 474.50 |
| Operating Profit After Depreciation | 1,569.80 | 779.30 | 169.20 | 403.50 | 603.70 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 2,286.70 | 2,233.80 | 2,174.20 | 2,005.90 | 1,574.50 |
| Total Non Current Assets | 3,143.60 | 2,893.20 | 2,810.30 | 2,584 | 2,406.80 |
| Total Current Assets | 3,410.40 | 2,494.70 | 2,167.70 | 2,168.50 | 2,239.90 |
| Total Assets | 6,554 | 5,387.90 | 4,978 | 4,752.50 | 4,646.70 |
| Total Shareholder's Fund | 5,592.30 | 4,702 | 4,191.90 | 4,091.10 | 3,869.50 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,196.40 | 784.40 | 57.70 | 183.50 | 422.50 |
| Net Cash Used In Investing Activities | -960.50 | -436.60 | -92.50 | -3.20 | -165 |
| Net Cash Used In Financing Activities | -237.30 | -346.80 | 35.60 | -183.10 | -261.10 |
| Particulars (in ₹ Cr.) | 2025-03 | 2024-12 | 2024-09 | 2024-06 | 2024-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,221 | 474.80 | 1,371.10 | 1,362.60 | 1,068.30 |
| Total Expenses | 672.90 | 436 | 566.80 | 557.80 | 571 |
| Profit Before Tax | 505.90 | 163.70 | 818.20 | 803.60 | 477.60 |
| Profit After Tax | 406 | 132.40 | 676.50 | 668.50 | 386.30 |
| Operating Profit after Depreciation | 614.40 | 215.10 | 868.10 | 852.90 | 539.30 |
| Particulars (in ₹ Cr.) | 2025-03 | 2024-12 | 2024-09 | 2024-06 | 2024-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,157.40 | 407.60 | 1,292.60 | 1,236.90 | 964.80 |
| Total Expenses | 596.20 | 378.20 | 501.90 | 473.90 | 512.10 |
| Profit Before Tax | 520.80 | 150.30 | 796.90 | 758 | 432.50 |
| Profit After Tax | 428.10 | 124.90 | 661.10 | 636.30 | 349.10 |
| Operating Profit after Depreciation | 623.30 | 197.40 | 842.10 | 802.80 | 488.60 |
Natco Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 975.23
S2 951.87
S3 938.03
Pivot 989.07
R1 1,012.43
R2 1,026.27
R3 1,049.63
Moving Average
20 SMA 902.62
50 SMA 874.61
100 SMA 868.95
200 SMA 1,117.99
Natco Pharma Ltd Corporate Actions
Natco Pharma Ltd
₹1.5/Share
Announcement Date 18 Feb 2025
Record Date 18 Feb 2025
Div Yield 75%
Natco Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,679.80 | ₹4,03,040.29 |
| Divis Laboratories Ltd | ₹6,883 | ₹1,82,722.02 |
| Cipla Ltd | ₹1,510.85 | ₹1,22,032.54 |
| Torrent Pharmaceuticals Ltd | ₹3,350.60 | ₹1,13,394.44 |
| Dr Reddys Laboratories Ltd | ₹1,310.05 | ₹1,09,334.39 |
Natco Pharma Ltd Top Mutal Funds Invested
Natco Pharma Ltd News
Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility
Natco Pharma announced that its pharmaceutical manufacturing facility in Kothur, Hyderabad, has received seven observations from the United States Food and Drug Administration (USFDA) following a recent inspection.
20 Jun 2025, 09:54 am
NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit
NATCO Pharma said that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 09 to 13 of June 2025.
14 Jun 2025, 01:45 pm
Natco Pharma's Mekaguda API unit completes USFDA inspection
13 Jun 2025, 04:27 pm
Natco Pharma Ltd gains for third consecutive session
Natco Pharma Ltd is quoting at Rs 908.15, up 3.01% on the day as on 12:49 IST on the NSE. The stock is down 22.31% in last one year as compared to a 8.09% spurt in NIFTY and a 11.76% spurt in the Nifty Pharma index.
11 Jun 2025, 01:05 pm
Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr
Natco Pharma added 3.73% to Rs 894.65 after the company's consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24.
29 May 2025, 03:50 pm
Natco Pharma Ltd Stock Analysis
- Annual revenue for Natco Pharma Ltd increased by 50.77% to ₹3,673.60 crore in FY 2024 from ₹2,436.50 crore in FY 2023.
- Annual Net Profit for Natco Pharma Ltd increased by 105.09% to ₹1,306.60 crore in FY 2024 from ₹637.10 crore in FY 2023.
- Promoter Shareholding in Natco Pharma Ltd decreased by 0.11% in the most recent quarter, from 49.62% in December 2024 to 49.56% in March 2025.
- Natco Pharma Ltd delivered a 1-year return of -17.87% compared to the Nifty 50, which provided a return of 4.77% as of the last trading session.
- Natco Pharma Ltd share price moved down by 2.50% from its previous close of INR ₹998.60. The latest Natco Pharma Ltd share price is INR ₹973.60.
- Natco Pharma Ltd share price today has been at a low of 970.30 and a high of 1,006. Over the past 52 weeks, the Natco Pharma Ltd share price has seen a low of 726.80 and a high of 1,639.
About Natco Pharma Ltd
Natco Pharma Ltd, founded in 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets. Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. Its expertise lies in developing and marketing specialised medicines, contributing significantly to healthcare accessibility.
Over decades, Natco Pharma has consistently expanded its operations, solidifying its position as a crucial contributor to the pharmaceutical sector. As a result, it has established a reputation for innovation and quality. The company has a team of professional managerial promoters who are
Natco Pharma Ltd. has profoundly impacted the pharmaceutical industry through its affordability, innovation, and quality commitment. The company’s efforts in developing generic medications, particularly in oncology, have made life-saving treatments accessible to many patients. Its ongoing dedication to improving healthcare outcomes ensures it will remain a vital player in its industry. This makes a positive difference in the lives of patients worldwide.
Over decades, Natco Pharma has consistently expanded its operations, solidifying its position as a crucial contributor to the pharmaceutical sector. As a result, it has established a reputation for innovation and quality. The company has a team of professional managerial promoters who are
- G S Murthy
- V C Nannapaneni
- Rajeev Nannapaneni
- T V Rao
- D G Prasad
Impact of Natco Pharma Limited
Natco Pharma Ltd. has significantly impacted the pharmaceutical industry in India and globally. The company’s contributions span various aspects. It includes developing affordable medicines and efforts to improve public health. This impact results from Natco Pharma’s commitment to innovation and accessibility. One of the most notable impacts of Natco Pharma is its role in making life-saving medications more affordable. The company has been at the forefront of producing generic versions of high-cost drugs. This is especially notable in the oncology segment. It has allowed patients to access important treatments at a fraction of the cost of branded medications. The availability of affordable generics has improved the quality of life for many patients. Natco Pharma’s focus on oncology has been particularly impactful. The company has developed and launched several generic cancer drugs. These drugs have provided cost-effective alternatives to expensive branded medications. It also helps to contribute to the overall improvement in cancer care. The company’s efforts in this area have been recognised globally. Natco Pharma continues to be a key player in the oncology pharmaceutical market. Natco Pharma’s impact extends beyond just providing medications. The company has invested in research and development to innovate and improve drug formulations. This focus on R&D has led to the development of new and improved medications that offer better efficiency and safety profiles. The company’s dedication to innovation ensures that it remains at the cutting edge of pharmaceutical advancements, continually bringing new solutions to the market. The company’s efforts in the agrochemical sector also highlight its broader impact. Its crop health sciences division develops products that help improve agricultural productivity. These agrochemical products support farmers in protecting their crops from pests and diseases. As a result, Natco Pharma's products contribute to food security and agricultural sustainability. This diversification into agrochemicals demonstrates its commitment to addressing various societal needs through its expertise in chemical formulations. Natco Pharma’s impact is also evident in its corporate social responsibility initiatives. The company actively engages in programs to improve education and community development. These initiatives are designed to uplift underprivileged communities and provide better opportunities and resources. Through its CSR efforts, Natco Pharma has made a positive difference in the lives of many individuals. This helps it to reinforce its role as a responsible corporate citizen. The company’s global presence further amplifies its impact. Natco Pharma exports its products to numerous countries. Doing this ensures patients worldwide can access affordable and effective medications. This reach has positioned Natco Pharma as a significant player in the pharmaceutical industry, helping it to contribute to improved healthcare outcomes globally.Natco Pharma Ltd. has profoundly impacted the pharmaceutical industry through its affordability, innovation, and quality commitment. The company’s efforts in developing generic medications, particularly in oncology, have made life-saving treatments accessible to many patients. Its ongoing dedication to improving healthcare outcomes ensures it will remain a vital player in its industry. This makes a positive difference in the lives of patients worldwide.
FAQ’s
What is the share price of Natco Pharma Ltd today?
Natco Pharma Ltd share price as on 7 Jul 2025 is ₹ 973.6
What is the Market Cap of Natco Pharma Ltd?
The market cap of Natco Pharma Ltd stock is ₹17,438.14 Cr.
What is the PE Ratio of Natco Pharma Ltd?
The Price to Earnings (P/E) Ratio of Natco Pharma Ltd is 13.04
What is the PB Ratio of Natco Pharma Ltd?
The Price to Book (P/B) Ratio of Natco Pharma Ltd is 3.05
What is the 52 week high of Natco Pharma Ltd Share Price?
The 52 week high of Natco Pharma Ltd share price stands at ₹1,639
What is the 52 week low of Natco Pharma Ltd Share Price?
The 52 week low of Natco Pharma Ltd share price stands at ₹726.80
How can I buy shares of Natco Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Natco Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
